Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640153 | 0.85 | GABRA5 (0.50) | ESR1ESR2GABRA5PTGS2PTGS1 | |
| SCHEMBL2475615 | 0.84 | MAPK14 (0.51) | GABRA5PTGS2PTGS1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3647123 | 0.82 | GABRA5 (0.56) | ESR1ESR2GABRA5PTGS2NPC1 | |
| SCHEMBL3639522 | 0.77 | GABRA5 (0.52) | ESR1ESR2GABRA5PTGS2NPC1 | |
| SCHEMBL259469 | 0.76 | GAA (0.51) | GABRA5SMN1; SMN2ALDH1A1 | |
| SCHEMBL3641134 | 0.73 | GABRA5 (0.49) | GABRA5 | |
| SCHEMBL3647167 | 0.73 | ESR1 (0.49) | ESR1ESR2GABRA5PTGS2PTGS1 | |
| SCHEMBL3644437 | 0.73 | GABRA5 (0.46) | ESR1ESR2GABRA5PTGS2 | |
| SCHEMBL2320527 | 0.72 | GABRA5 (0.52) | ESR1ESR2GABRA5PTGS2PTGS1 | |
| SCHEMBL3645874 | 0.72 | GABRA5 (0.52) | ESR1ESR2GABRA5PTGS2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170873-B1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-7851469-B2 | Isoxazole-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2170873-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009000662-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | GABRA5, GABRA1, GABRA4 | ESR1 721/4885ESR2 814/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.